Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ana Maria Gimenez-Arnau

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
European Journal of Dermatology : EJD|April 1, 2024
Biomarkers to predict therapeutic response in chronic spontaneous urticaria: a reviewAna Maria Gimenez-Arnau, Andaç Salman, Indrashis Podder
The Journal of Dermatological Treatment|March 2, 2019
Real-life data on the effectiveness and safety of omalizumab in monotherapy or combined for chronic spontaneous urticaria: a retrospective cohort studyAndac Salman, Tulin Ergun, Ana Maria Gimenez-Arnau
Dermatology and Therapy|September 30, 2023
Omalizumab for Patients with Chronic Spontaneous Urticaria: A Narrative Review of Current StatusThomas B Casale, Ana Maria Gimenez-Arnau, Jonathan A Bernstein, et al.
Anais Brasileiros De Dermatologia|May 25, 2021
What lessons can we learn? Clinical and epidemiological retrospective analysis of 267 patients with urticaria in a Brazilian tertiary centerRoberta Fachini Jardim Criado, Paulo Ricardo Criado, Nathalia Baldavira, et al.
Allergy|August 19, 2023
Efficacy and safety of on-demand versus daily rupatadine in chronic spontaneous urticaria: A randomized trialKarsten Weller, Ana Maria Gimenez-Arnau, Jens Baron, et al.
Expert Review of Clinical Immunology|November 18, 2024
Biological drugs for the treatment of children with chronic spontaneous urticariaIndrashis Podder, Andaç Salman, Riccardo Asero, et al.
Clinical and Translational Allergy|October 25, 2023
Differential diagnosis between urticarial vasculitis and chronic spontaneous urticaria: An international Delphi surveyKaroline Krause, Hanna Bonnekoh, Jannis Jelden-Thurm, et al.
Lancet (London, England)|November 26, 2023
Efficacy and safety of ligelizumab in adults and adolescents with chronic spontaneous urticaria: results of two phase 3 randomised controlled trialsMarcus Maurer, Luis Felipe Ensina, Ana Maria Gimenez-Arnau, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
European Journal of Dermatology : EJD|April 1, 2024
Biomarkers to predict therapeutic response in chronic spontaneous urticaria: a reviewAna Maria Gimenez-Arnau, Andaç Salman, Indrashis Podder
The Journal of Dermatological Treatment|March 2, 2019
Real-life data on the effectiveness and safety of omalizumab in monotherapy or combined for chronic spontaneous urticaria: a retrospective cohort studyAndac Salman, Tulin Ergun, Ana Maria Gimenez-Arnau
Dermatology and Therapy|September 30, 2023
Omalizumab for Patients with Chronic Spontaneous Urticaria: A Narrative Review of Current StatusThomas B Casale, Ana Maria Gimenez-Arnau, Jonathan A Bernstein, et al.
Anais Brasileiros De Dermatologia|May 25, 2021
What lessons can we learn? Clinical and epidemiological retrospective analysis of 267 patients with urticaria in a Brazilian tertiary centerRoberta Fachini Jardim Criado, Paulo Ricardo Criado, Nathalia Baldavira, et al.
Allergy|August 19, 2023
Efficacy and safety of on-demand versus daily rupatadine in chronic spontaneous urticaria: A randomized trialKarsten Weller, Ana Maria Gimenez-Arnau, Jens Baron, et al.
Expert Review of Clinical Immunology|November 18, 2024
Biological drugs for the treatment of children with chronic spontaneous urticariaIndrashis Podder, Andaç Salman, Riccardo Asero, et al.
Clinical and Translational Allergy|October 25, 2023
Differential diagnosis between urticarial vasculitis and chronic spontaneous urticaria: An international Delphi surveyKaroline Krause, Hanna Bonnekoh, Jannis Jelden-Thurm, et al.
Lancet (London, England)|November 26, 2023
Efficacy and safety of ligelizumab in adults and adolescents with chronic spontaneous urticaria: results of two phase 3 randomised controlled trialsMarcus Maurer, Luis Felipe Ensina, Ana Maria Gimenez-Arnau, et al.
Pageof 1